Associations between polymorphisms of the ACYP2 gene and Liver cancer risk: A case‐control study and meta‐analysis

Abstract

Background ACYP2 gene may be involved in the process of telomere shortening which may be involved in the liver cancer. So, this research was to examine whether the ACYP2 gene polymorphism has impact on the risk of liver cancer in Chinese population. Methods Two hundred and fifty cirrhosis patients and 248 liver cancer patients were selected. Unconditional logistic regression was to calculate the odds ratio (OR) and 95% confidence intervals (CIs). Analyze the relationship between ACYP2 gene polymorphism and tumor using meta‐analysis. Analyze the expression of ACYP2 gene in liver cancer and its influence on the prognosis of liver cancer by databases (Ualcan, GTEX and Kaplan–Meier plotter). Results In the allele model, ACYP2 rs843720 was protection against the occurrence of cirrhosis developed into liver cancer (OR = 0.76, 95% CI: 0.58–0.99, p = 0.04). Rs1682111 and rs843720 play a protective role in the additive model (rs1682111: OR = 0.69, 95% CI: 0.52–0.93, p = 0.01; rs843720: OR = 0.73, 95% CI: 0.54–0.98, p = 0.04).While rs843645 G allele increased the risk of cirrhosis developed into liver cancer under the additive model (OR = 1.42, 95% CI: 1.02–2.00, p = 0.04).The haplotype analysis detected that “ATATCGCC” decreased the risk of cirrhosis developed into liver cancer (OR = 0.69, 95% CI: 0.51–0.92, 95% CI: p = 0.013); however, “TGAGCGTC” increased the risk of cirrhosis developed into liver cancer (OR = 1.48, 95% CI: 1.04–2.10, p = 0.027). Meta‐analysis shown that ACYP2 rs1682111 was associated with the risk of cancer (OR = 0.90, 95% CI: 0.78–1.05, p = 0.02). ACYP2 gene high expression was found to be associated with better OS for all liver patients. Conclusion Based on this research, we surmised that ACYP2 gene may be involved in the occurrence of liver cancer in Chinese populations.

Study of the effect of ACYP2 single nucleotide polymorphisms rs843711 and rs843706 in Egyptian patients with hepatocellular carcinoma

“…No statistical difference was found between both groups. Similarly, Zhao et al, 2019 6 reported similar results and concluded that the rs843711 genotypes were not associated with the incidence of HCC. Meanwhile, our results disagreed with those of Huang et al, 2020 18 who reported an association between the TT genotype of rs843711 and incidence of HCC (p < 0.05).…”

“…Our results disagreed with data of the meta-analysis study conducted by Chang et al, 2022 19 which found that ACYP2 rs843706, rs843711 mutations had a significant association with increasing the risk of HCC. Meanwhile, the meta-analysis conducted by Zhao et al, 2019 6 revealed no statistically significant difference in the relationship between ACYP2 gene polymorphism and cirrhosis developed into liver cancer in selected 13 SNPs using real time PCR. The meta-analysis reported that neither rs843706 nor rs843711 polymorphisms influenced the risk of liver cancer.…”

“…Polymorphisms of ACYP2 gene have been associated with shorter telomere length, escape from apoptosis and promotion of carcinogenesis. 6 Studies have shown that polymorphisms of ACYP2 were associated with lung cancer, 7 colorectal cancer, 8 breast cancer 9 , gastric cancer, 10 liver cancer. 11 The aim of the current study was to assess the association between ACYP2 single nucleotide gene polymorphisms (rs843711), and (rs843706) and increased incidence of HCC in Egyptians.…”

A novel 16-gene alternative mRNA splicing signature predicts tumor relapse and indicates immune activity in stage I–III hepatocellular carcinoma

“…For example, ACYP2 was reported to contribute to the malignant progression of glioma by promoting Ca 2+ efflux and the subsequent activation of c-Myc and STAT3 signals ( Li et al, 2020 ). Moreover, ACYP2 gene polymorphism was associated with the risk of cirrhosis developing into liver cancer, and high ACYP2 expression was associated with better overall survival in HCC, which indicated its important role in HCC progression ( Zhao et al, 2019b ). ANXA1 was highlighted as a biomarker in oncology, and manipulation of ANX1 in cancers can influence the metastatic behavior of the tumor cells by modulating inflammation, immune response, and angiogenesis ( Delorme et al, 2021 ).…”